HRTX (34) PLRX (34) TLPH (36) HYFT (45) ⌘ Pro Terminal →

Xilio Therapeutics Inc. (XLO) — RQD Stock Rating Cockpit

$8.03 +3.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.06

Xilio Therapeutics Inc. (XLO) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (25/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $52.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on XLO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is XLO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Xilio Therapeutics Inc. (NASDAQ: XLO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $8.03 (+3.35% 1D, market cap $52.8M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, XLO ranks #933 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does XLO compare to HRTX and PLRX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XLO carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HRTX (Heron Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $52.7M) and PLRX (Pliant Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $53.2M). Among the 5-stock peer group, XLO leads on earnings multiple (N/A) while XLO leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for XLO?

▼

Per XLO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840233), Xilio Therapeutics Inc. generated $43.8M in revenue (+589.9% YoY), -$35.0M in net income, and -$5.5M in free cash flow against $154.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $8.06 (+0.41%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (25/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-14.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XLO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (25/100 Composite)

🔍 WHY XLO SCORES 25/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (32% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$9.07-8.2% Next Q

Q2 (-2Q)

Grade E$8.33-12.2% Next Q

Q3 (-1Q)

Grade E$7.31+9.8% Next Q

Current

Grade E$8.03-10.7% Hist 90D α

Trajectory: E (33) → E (25)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a XLO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While XLO currently carries a cautious 25/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.78) and Max Pain ($8.43) forces dealer call-delta covering toward $12.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XLO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “XLO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 25%NO 75%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

42.130 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.20>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE27% OF RANGE

L: $6$8.03H: $12

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 7 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 13 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on XLO

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (25)

-35.0% ROIC with 42.0% gross margin and -10.78% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (40)

Altman-Z 0.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (20)

7/40 institutional & smart-money positioning score with 5/20 macro alignment.

Bull Case: Why Buyers Like XLO

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XLO)

✓Walkthrough of XLO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

XLO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -3.60%📐 HORIZONTAL RANGE

2026-11-03O $7.77H $8.03L $7.77C $8.03VOL 7.9K

RES: $9.92SUP: $6.95SMA50: $8.78SMA200: $8.49

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XLO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XLO Butterfly Map → + Track XLO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on XLO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XLO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for XLO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XLO)

Health Care Rank #933 of 1016 ⚔️ HRTX vs XLO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XLO vs. HRTX, PLRX, TLPH, HYFT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Xilio Therapeutics Inc. (XLO) ranks #933 by composite RQD confidence (25/100, grade E) and #738 by equity capitalization ($52.8M). Within this direct 5-issuer industry benchmark cohort, XLO leads on earnings valuation at N/A trailing P/E, while XLO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. HYFT currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with XLO at 25/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
XLO ACTIVE Xilio Therapeutics Inc.	E	25/100	—	—	-35.0%	+3.35%	$52.8M	Benchmark Subject
HRTX Heron Therapeutics Inc.	E	34/100	—	73.3%	-35.0%	-5.67%	$52.7M	/hrtx-vs-xlo →
PLRX Pliant Therapeutics Inc.	E	34/100	—	—	-35.0%	-0.13%	$53.2M	/plrx-vs-xlo →
TLPH Talphera Inc.	D-	36/100	—	—	-35.0%	-3.74%	$53.5M	/tlph-vs-xlo →
HYFT MindWalk Holdings Corp.	D	45/100	—	—	—	-5.83%	$53.8M	/hyft-vs-xlo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001840233

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xilio Therapeutics Inc. (XLO) reported GAAP revenue of $43.8M (+589.9% vs. FY2024 revenue of $6.3M ) , GAAP net income of -$35.0M, operating cash flow of -$5.0M, and free cash flow of -$5.5M (+70.1% YoY). On the balance sheet, XLO closed FY2025 with $154.7M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$43.8M	-$35.0M	-$5.0M	-$5.5M	$154.7M	—
FY2024 (FY)	2024-12-31	$6.3M	-$58.2M	-$18.4M	-$18.4M	$71.1M	—
FY2023 (FY)	2023-12-31	$0	-$76.4M	-$68.6M	-$68.6M	—	—

3. XLO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XLO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does XLO compare to HRTX and PLRX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for XLO?

Where is XLO trading relative to its 50-day, 200-day, and 52-week technical levels?

XLO last traded at $8.03 (+3.35% on volume of 7,919 shares), positioning the stock -8.54% below its 50-day simple moving average ($8.78) and -5.42% below its 200-day simple moving average ($8.49). Across its 52-week range of $6.47 to $12.32, XLO sits at the 26.7% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.03 to $9.03).

XLO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell XLO stock right now?

Xilio Therapeutics Inc. (XLO) currently earns a Roarable Rating of E (Strong Sell — SELL) with 25/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is XLO's 12-month price target and RQD AI Jury consensus?

XLO's 12-month base price target is $6.84 (range $5.34 to $12.94), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: XLO RQD Cockpit XLO 12M Forecast XLO Earnings & Move XLO Dividends & DRIP XLO Insiders & 13F XLO Whale Options XLO Profit Sankey XLO News & Why

ROARABLE RATING BRIEF • RQD 25/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

XLO — Xilio Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:46:50Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, XLO scores 27 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine 5/20 (ROIC -35%; FCF yield -10.78%); Whale 13F Flow 5/20 (institutional accumulation and options positioning); Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 6/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet 8/20 (Altman Z 0.2; Piotroski F 4/9; Debt/Equity 0.5). For a prospective investor, the lowest-scoring pillars indicate that cash generation, insider signaling, and institutional support are all weak relative to the framework's standards. The forensic pillar's low Altman Z-Score points to elevated financial-distress risk, while the Beta of 1.0 means the stock's market sensitivity is neutral on this metric. Any upside case would need to rest on catalysts outside the current cash-engine and balance-sheet profile, which the rating treats as the dominant risk.

Recent Catalysts & News Wire Analysis

Analyst initiation (GREEN, CATALYST): Per the news feed, Raymond James initiated coverage with an outperform rating.
Clinical milestone (YELLOW, MARKET WIRE): Per the news feed, Xilio announced the first patient dosed in a Phase 1/2 trial of XTX501 in patients with metastatic NSCLC. Per the Stock Titan report, initial results are expected in the fourth quarter of 2027.
Earnings expectation (YELLOW): Per the TradingView report, the Q3'26 revenue estimate is 4.92M USD.
Price action (YELLOW): Per the news feed, shares were reported edging lower to $9.00 within a defined range; this conflicts with the $8.03 price in market data and may reflect a different timestamp.
Unrelated item (YELLOW): A Yahoo! Finance Canada item concerns Adagene Inc. (ADAG), not XLO.
Proprietary signals: Not available in source data (Butterfly graph returns no signals).

Open Questions

What is the company's debt balance, given that debt is reported as N/A in every period?
What were FY 2025 EPS and share count, given EPS is reported as N/A throughout?
What partnership or revenue source generated the $43.8M FY 2025 revenue?
Which insider and institutional transactions drive the 3/20 and 5/20 pillar scores?
Does the $9.00 price cited in the news feed reflect a different timestamp from the $8.03 market price?

XLO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Xilio Therapeutics Inc. (XLO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to XLO Debate Forum (3) ↓

🟢 CATALYST Investing.com • 17h ago

Raymond James initiates Xilio Therapeutics stock with outperform rating

Investing.com report covering Xilio Therapeutics Inc. (XLO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 20h ago

Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC

Yahoo Finance report covering Xilio Therapeutics Inc. (XLO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 23h ago

XLO Q3'26 Earnings: revenue estimate is 4.92M USD

TradingView report covering Xilio Therapeutics Inc. (XLO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

An experimental lung cancer drug has reached its first patient. Xilio expects initial results in the fourth quarter of 2027.

Stock Titan report covering Xilio Therapeutics Inc. (XLO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Xilio Therapeutics (XLO) Edges Lower to $9.00 as Shares Consolidate Within a Defined Range - VWAP Bounce

https://www.siam.in/ report covering Xilio Therapeutics Inc. (XLO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Adagene Inc. (ADAG) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Xilio Therapeutics Inc. (XLO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Connect Biopharma Holdings Limited (CNTB) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Xilio Therapeutics Inc. (XLO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 8d ago

Xilio Therapeutics Doses First Participant In Its Phase 1/2 Clinical Study Of XTX501 To Treat Metastatic Non-Small Cell Lung Cancer

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that the first patient has been

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

XLO Bull vs. Bear Conversation Board — What's Your Call at $8.03?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON XLO 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $7.07 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is XLO (E • RQD 27/100) a Buy at $8.03?

Welcome to the XLO (Xilio Therapeutics Inc.) Roar Pit. Current RQD Composite is 27/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $6.26 (-22.0%)

Spot @ $8.03

Pump the brakes on XLO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on XLO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Xilio Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $10.04 (+25.0%)

Spot @ $8.03

XLO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on XLO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $8.03 (52-wk range $6.47 - $12.32), any beat on forward guidance forces shorts and underweight funds to chase.